Literature DB >> 30948845

Parkinson disease and growth factors - is GDNF good enough?

Agnete Kirkeby1, Roger A Barker2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30948845     DOI： 10.1038/s41582-019-0180-6

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  1 in total

1.  Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease.

Authors:  Alan L Whone; Mihaela Boca; Matthias Luz; Max Woolley; Lucy Mooney; Sonali Dharia; Jack Broadfoot; David Cronin; Christian Schroers; Neil U Barua; Lara Longpre; C Lynn Barclay; Chris Boiko; Greg A Johnson; H Christian Fibiger; Rob Harrison; Owen Lewis; Gemma Pritchard; Mike Howell; Charlie Irving; David Johnson; Suk Kinch; Christopher Marshall; Andrew D Lawrence; Stephan Blinder; Vesna Sossi; A Jon Stoessl; Paul Skinner; Erich Mohr; Steven S Gill
Journal:  J Parkinsons Dis       Date:  2019       Impact factor: 5.568
  1 in total
  11 in total

Review 1.  Therapeutic Strategies for Immune Transformation in Parkinson's Disease.

Authors:  Maamoon Saleh; Milica Markovic; Katherine E Olson; Howard E Gendelman; R Lee Mosley
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

Review 2.  Glial cell line-derived neurotrophic factors (GFLs) and small molecules targeting RET receptor for the treatment of pain and Parkinson's disease.

Authors:  Arun Kumar Mahato; Yulia A Sidorova
Journal:  Cell Tissue Res       Date:  2020-06-17       Impact factor: 5.249

Review 3.  Extracellular Vesicles as Nanotherapeutics for Parkinson's Disease.

Authors:  Loredana Leggio; Greta Paternò; Silvia Vivarelli; Francesca L'Episcopo; Cataldo Tirolo; Gabriele Raciti; Fabrizio Pappalardo; Carmela Giachino; Salvatore Caniglia; Maria Francesca Serapide; Bianca Marchetti; Nunzio Iraci
Journal:  Biomolecules       Date:  2020-09-16

Review 4.  Improving therapeutic potential of GDNF family ligands.

Authors:  Pia Runeberg-Roos; Richard D Penn
Journal:  Cell Tissue Res       Date:  2020-07-28       Impact factor: 5.249

5.  The Future of GDNF in Parkinson's Disease.

Authors:  Fredric P Manfredsson; Nicole K Polinski; Thyagarajan Subramanian; Nicholas Boulis; Dustin R Wakeman; Ronald J Mandel
Journal:  Front Aging Neurosci       Date:  2020-12-07       Impact factor: 5.750

6.  BMP5/7 protect dopaminergic neurons in an α-synuclein mouse model of Parkinson's disease.

Authors:  Zagorka Vitic; Hazem Safory; Vukasin M Jovanovic; Yael Sarusi; Alexandra Stavsky; Joy Kahn; Alona Kuzmina; Lilah Toker; Daniel Gitler; Ran Taube; Roland H Friedel; Simone Engelender; Claude Brodski
Journal:  Brain       Date:  2021-03-03       Impact factor: 13.501

7.  Failure of Glial Cell-Line Derived Neurotrophic Factor (GDNF) in Clinical Trials Orchestrated By Reduced NR4A2 (NURR1) Transcription Factor in Parkinson's Disease. A Systematic Review.

Authors:  Piniel Alphayo Kambey; Kouminin Kanwore; Abiola Abdulrahman Ayanlaja; Iqra Nadeem; YinZhen Du; Wokuheleza Buberwa; WenYa Liu; Dianshuai Gao
Journal:  Front Aging Neurosci       Date:  2021-02-24       Impact factor: 5.750

Review 8.  Is activation of GDNF/RET signaling the answer for successful treatment of Parkinson's disease? A discussion of data from the culture dish to the clinic.

Authors:  James A Conway; Edgar R Kramer
Journal:  Neural Regen Res       Date:  2022-07       Impact factor: 5.135

9.  An alginate-based encapsulation system for delivery of therapeutic cells to the CNS.

Authors:  Despoina Eleftheriadou; Rachael E Evans; Emily Atkinson; Ahmed Abdalla; Francesca K H Gavins; Ashleigh S Boyd; Gareth R Williams; Jonathan C Knowles; Victoria H Roberton; James B Phillips
Journal:  RSC Adv       Date:  2022-02-01       Impact factor: 3.361

Review 10.  Recent developments in the treatment of Parkinson's Disease.

Authors:  Thomas B Stoker; Roger A Barker
Journal:  F1000Res       Date:  2020-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.